

ENTEGRIS BOLSTERED OPERATIONAL RESPONSE TO COVID-19

We understand that during these uncertain times, trusted supply chain partners are needed and relied upon more than ever. You can be certain that we are committed to remaining a strong partner for you and as such, have dedicated ourselves these past months on the following activities.

Maintaining Critical Operations

Relying on our business continuity plans and leveraging relationships with trusted supply chain partners, we have maintained our critical operations through the most restrictive phase of the COVID-19 response, continuing production with minimal disruption and shipping on time. In short, our exemplary team stepped up and continues to do so to maintain our performance despite future uncertainties.

We are playing a supporting but crucial role in our customers' efforts to develop and manufacture therapies for COVID-19. We are currently undergoing rapid scale up to meet commercial demand for the pipeline of potential successful candidates. Therefore, we are closely monitoring additional short- and long-range scaleup plans and welcome forecasts for ongoing and future projects.

Maintaining Accessibility

Our product solutions, and the workflows they are used within, require a specific level of quality risk management discipline to be compliant with GMP regulatory requirements. In today's business context, site-to-site travel is limited, which may impact access to facilities and subject matter experts. In response, we have taken steps to enable supplier and process qualification by participating in the BioPhorum Operations Group – Joint Audit Program, significantly updating our Aramus™ 2D bag assembly validation guide, and providing valuable subject matter insights.

- BioPhorum and Rx-360 worked together to create the Joint Audit Model in the single-use systems supply chain with the aim to deliver consistent, rigorous, and cost-effective quality audits that will alleviate the audit burden while ensuring biopharmaceutical manufacturers are in control of their supply chain. The in-depth two-day audit of Entegris was completed on January 7 and 8, 2020, at our Bloomington, MN facility and was performed by the British Standards Institute (BSI). Our audit report can be licensed through Rx-360 by contacting Jaye Greene, head of audit operations at Rx-360 at jgreene@rx-360.org.
- The Aramus 2D bag assembly validation guide improvements increase transparency of qualification activities that were already included in the guide and include valuable new product qualification and validation summaries that help assess fit for purpose needed to implement Aramus 2D bag assemblies into your process. Please contact an account manager to request a copy of our updated guide.
- We have continued to engage our customers with valuable subject matter expertise. Recently, our Cold-chain Applications Engineer, Muhammad Siddiqui, provided a webinar on *Risk Mitigation for Single-use Cold-chain Distribution* where he addressed cold-chain distribution, which is becoming a more critical part of the drug therapy supply chain. A recording of the webinar can be accessed here: [View Webinar](#)

We are committed to helping you solve your most critical process challenges, and you can be certain we will continue taking proactive steps to be a secure and reliable partner. If you are interested in contacting Entegris for more information, [please click here](#).

Sincerely,

The Life Sciences Team